Prophylactic ANTicoagulation With HEparine in Critically Ill Patients With Renal Impairment
PANTHER
1 other identifier
observational
1,111
1 country
15
Brief Summary
Intensive care patients have an increased risk of venous thromboembolic events (deep vein thrombosis (DVT) and pulmonary embolism (PE)) due to the presence of general risk factors for thrombosis (age, immobilization, obesity, prothrombotic history, etc.), but also risk factors specifically related to their stay in intensive care (sepsis, vasopressors, organ failure, mechanical ventilation, sedation, renal failure, central venous catheters). In addition, these same patients also have an increased risk of hemorrhagic events, mainly associated with coagulation disorders and thrombocytopenia. Given this increased risk of thrombosis, it is recommended that heparin thromboprophylaxis be used in intensive care patients in the absence of contraindications. In current practice, when faced with a patient with impaired renal function, there is significant heterogeneity in the prescription of thromboprophylaxis between centers and intensive care physicians: some will use enoxaparin, dalteparin, or tinzaparin regardless of renal function, while others will use subcutaneous calciparin or IVSE UFH. The PANTHER study is a prospective, multicenter, observational study that aims to evaluate the safety and efficacy of heparin thromboprophylaxis in critically ill patients with renal failure. The goal is to assess whether there is a difference in bleeding risk and thromboprophylaxis efficacy depending on the molecule used.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2026
Typical duration for all trials
15 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2026
CompletedFirst Submitted
Initial submission to the registry
January 16, 2026
CompletedFirst Posted
Study publicly available on registry
January 26, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
February 1, 2028
January 26, 2026
December 1, 2025
2.1 years
January 16, 2026
January 16, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Incidence of hemorrhagic and thrombotic events in patients with renal failure in intensive care receiving heparin thromboprophylaxis
Incidence of hemorrhagic and thrombotic events was evaluated by occurrence of major bleeding and occurrence of a venous thromboembolic event
Day 1 to Day 28
Study Arms (1)
patient with impaired renal function in intensive care
Eligibility Criteria
Patient with impaired renal function in intensive care
You may qualify if:
- Presence of impaired renal function (one of the two criteria must be met, both criteria may be met):
- Glomerular filtration rate (GFR) \<30ml/min/1.7m² according to the MDRD or CKD-EPI formula.
- Acute renal failure (observed or presumed increase in creatinine in the last 7 days) KDIGO stage 3 (creatinine ≥3 times baseline creatinine or ≥354 µmol/L (4 mg/dL) or urine output \<0.3 mL/kg/h for ≥24 hours or initiation of extrarenal clearance or anuria for ≥12 hours)
- \- Expected length of stay in intensive care ≥48 hours
You may not qualify if:
- Age ≤ 18 years
- Long-term dialysis patient
- Current or recent hemorrhage during this hospitalization
- Patient receiving curative anticoagulation or treated long-term prior to admission with curative anticoagulation.
- Thrombosis present on admission
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (15)
CHU Angers
Angers, 49000, France
CHU bordeaux
Bordeaux, 33000, France
CHU Brest
Brest, 29609, France
CHU Caen
Caen, 14000, France
Centre Hospitalier Le Mans
Le Mans, 72000, France
Groupe Hospitalier Bretagne Sud
Lorient, 56322, France
CHR Metz-Thionville site Mercy
Metz, 57000, France
CHRU Nancy
Nancy, 54511, France
CHU Nantes
Nantes, 44000, France
CHU Orléans
Orléans, 45100, France
CHU Poitiers
Poitiers, 86000, France
CHU Rennes
Rennes, 35000, France
Centre Hospitalier de Saint-Nazaire
Saint-Nazaire, 44600, France
CHR Metz-Thionville Hôpital Bel-Air
Thionville, 57100, France
CHU Tours
Tours, 37000, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 16, 2026
First Posted
January 26, 2026
Study Start
January 1, 2026
Primary Completion (Estimated)
February 1, 2028
Study Completion (Estimated)
February 1, 2028
Last Updated
January 26, 2026
Record last verified: 2025-12